These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37695700)

  • 1. Advances in the systemic therapy for recurrent meningiomas and the challenges ahead.
    Li Y; Drappatz J
    Expert Rev Neurother; 2023; 23(11):995-1004. PubMed ID: 37695700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current treatment options for meningioma.
    Apra C; Peyre M; Kalamarides M
    Expert Rev Neurother; 2018 Mar; 18(3):241-249. PubMed ID: 29338455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Atypical and Anaplastic Meningiomas.
    Buttrick S; Shah AH; Komotar RJ; Ivan ME
    Neurosurg Clin N Am; 2016 Apr; 27(2):239-47. PubMed ID: 27012388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current experimental therapies for atypical and malignant meningiomas.
    Corona AM; Di L; Shah AH; Crespo R; Eichberg DG; Lu VM; Luther EM; Komotar RJ; Ivan ME
    J Neurooncol; 2021 Jun; 153(2):203-210. PubMed ID: 33950341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical meningiomas.
    Chen R; Aghi MK
    Handb Clin Neurol; 2020; 170():233-244. PubMed ID: 32586495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.
    Lou E; Sumrall AL; Turner S; Peters KB; Desjardins A; Vredenburgh JJ; McLendon RE; Herndon JE; McSherry F; Norfleet J; Friedman HS; Reardon DA
    J Neurooncol; 2012 Aug; 109(1):63-70. PubMed ID: 22535433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Necrosis is a consistent factor to recurrence of meningiomas: should it be a stand-alone grading criterion for grade II meningioma?
    Góes P; Santos BFO; Suzuki FS; Salles D; Stávale JN; Cavalheiro S; de Paiva Neto MA
    J Neurooncol; 2018 Apr; 137(2):331-336. PubMed ID: 29270884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A narrative review of targeted therapies in meningioma.
    Kim L
    Chin Clin Oncol; 2020 Dec; 9(6):76. PubMed ID: 33353364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innovative treatments for meningiomas.
    Graillon T; Tabouret E; Salgues B; Horowitz T; Padovani L; Appay R; Farah K; Dufour H; Régis J; Guedj E; Barlier A; Chinot O
    Rev Neurol (Paris); 2023 Jun; 179(5):449-463. PubMed ID: 36959063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. World Health Organization Grade III Meningiomas: A Retrospective Study at an Academic Medical Center.
    Sá-Marta E; Alves JL; Rebelo O; Barbosa M
    World Neurosurg; 2021 May; 149():e877-e893. PubMed ID: 33516862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases.
    Palma L; Celli P; Franco C; Cervoni L; Cantore G
    J Neurosurg; 1997 May; 86(5):793-800. PubMed ID: 9126894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the results of recurrent intracranial meningiomas treated with re-radiosurgery.
    Kim M; Lee DH; Kim Rn HJ; Cho YH; Kim JH; Kwon DH
    Clin Neurol Neurosurg; 2017 Feb; 153():93-101. PubMed ID: 28081463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of Pharmacotherapy in Treatment of Meningiomas].
    Tamura R
    No Shinkei Geka; 2024 Jul; 52(4):825-838. PubMed ID: 39034520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.
    Schrell UM; Rittig MG; Anders M; Koch UH; Marschalek R; Kiesewetter F; Fahlbusch R
    J Neurosurg; 1997 May; 86(5):840-4. PubMed ID: 9126900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Landscape of genetic variants in sporadic meningiomas captured with clinical genomics.
    Leclair NK; Shen E; Wu Q; Wolansky L; Becker K; Li L; Bulsara KR
    Acta Neurochir (Wien); 2022 Sep; 164(9):2491-2503. PubMed ID: 35881312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma.
    Mason WP; Gentili F; Macdonald DR; Hariharan S; Cruz CR; Abrey LE
    J Neurosurg; 2002 Aug; 97(2):341-6. PubMed ID: 12186462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of adjuvant radiotherapy for atypical and anaplastic meningioma.
    Zhu H; Bi WL; Aizer A; Hua L; Tian M; Den J; Tang H; Chen H; Wang Y; Mao Y; Dunn IF; Xie Q; Gong Y
    Cancer Med; 2019 Jan; 8(1):13-20. PubMed ID: 30680963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical and anaplastic meningiomas treated with bevacizumab.
    Nayak L; Iwamoto FM; Rudnick JD; Norden AD; Lee EQ; Drappatz J; Omuro A; Kaley TJ
    J Neurooncol; 2012 Aug; 109(1):187-93. PubMed ID: 22544653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgical resection and permanent brachytherapy for recurrent atypical and malignant meningioma.
    Ware ML; Larson DA; Sneed PK; Wara WW; McDermott MW
    Neurosurgery; 2004 Jan; 54(1):55-63; discussion 63-4. PubMed ID: 14683541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas.
    Sioka C; Kyritsis AP
    J Neurooncol; 2009 Mar; 92(1):1-6. PubMed ID: 19023520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.